While provider attitudes and aspects of the health system are likely to be implicated [11], [12], a reluctance to start insulin therapy has been shown to occur in at least one-quarter of insulin-naïve people with type 2 diabetes [13]. This evidence concerns the gene INS and type 2 diabetes mellitus.